InvestorsHub Logo
Followers 8
Posts 1891
Boards Moderated 0
Alias Born 05/05/2016

Re: thesaud post# 20648

Friday, 02/22/2019 9:56:42 AM

Friday, February 22, 2019 9:56:42 AM

Post# of 44784

Too many positives for failure!

I agree! It's quite impressive, what they have achieved, with a fairly low expenditure of resources.

Lot's of collaborations with the medical and academic community. When we see the constant stream of patents for an astonishing variety of ailments (including aging), it gives you a good idea of the power and potential of this platform.

They're playing a careful game of chess, laying out the pieces in a systematic, methodical way, including the all important manufacturing process and delivery methods. Much of this comes from collaborators, specialists in a variety of areas (such as the effects of weightlessness and radiation in space). This amplifies the power of the platform in ways that Pluristem could not achieve with its own science staff (the MSC platform is just too big).

In the meanwhile the clinical studies are moving us toward eventual approval in specific indications, many of which have broad implications. For example, PLX-PAD's arena is regeneration of tissue perfusion functions, this is useful beyond CLI, it's applicable to a whole cluster of diseases that have occlusion as the common denominator. The same for R18, radiation damage is a common problem in various therapies, so if the cells are good for Chernobyl/Fukushima victims, it will be useful for patients getting therapeutic radiation.

All this will be very obvious as we get more positive feedback from ongoing trials, and getting closer to approval for ANY indications. I agree with Allo that at some point we could see a massive breakout.

BTW, to the "uncanny" ones, daily "predictions" of pps are an exercise in futility! I "belieb" so is "LMBO", which is an outright danger to your health.